MAPK1 and central nervous system cancer: BRAF V600E-mutated PA appears to be associated with an inferior prognosis compared to PA with wild-type BRAF, which may be due to the fact that class I mutations are such strong drivers of ERK signaling and correlate with the relative absence of BRAF fusions in high-grade glioma [72].